Rezvilutamide

In today's world, Rezvilutamide has become a highly relevant issue and its impact is reflected in different areas of society. Its influence ranges from political and economic to cultural and social aspects. It is a topic that has sparked great interest and generated debate at all levels, from academic circles to everyday conversations. In this article, we will explore different facets of Rezvilutamide and analyze its impact today, as well as the possible implications it has for the future.
Rezvilutamide
Clinical data
Other namesSHR3680
Drug classNonsteroidal antiandrogen
Identifiers
  • 4-phenyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile
CAS Number
PubChem CID
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H20F3N3O4S
Molar mass479.47 g·mol−1
3D model (JSmol)
  • CC1(C(=O)N(C(=S)N1C2=CC=C(C=C2)OC(CO)O)C3=CC(=C(C=C3)C#N)C(F)(F)F)C
  • InChI=1S/C22H20F3N3O4S/c1-21(2)19(31)27(15-4-3-13(10-26)18(9-15)22(23,24)25)20(33)28(21)14-5-7-17(8-6-14)32-12-16(30)11-29/h3-9,16,29-30H,11-12H2,1-2H3/t16-/m0/s1
  • Key:KRBMOYIWQCZVHA-INIZCTEOSA-N

Rezvilutamide (INNTooltip International Nonproprietary Name), sold under the brand name Ariane, is a nonsteroidal antiandrogen which is approved for the treatment of prostate cancer in China and is or was under development for the treatment of breast cancer. It is a selective androgen receptor antagonist with reduced brain distribution compared to the structurally related nonsteroidal antiandrogen enzalutamide. The drug was developed by Jiangsu Hengrui Medicine. Other structural analogues of rezvilutamide that are also used as antiandrogens besides enzalutamide include apalutamide and proxalutamide.

References

  1. ^ "Rezvilutamide". chemidplus. U.S. National Library of Medicine.
  2. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO.
  3. ^ a b c "SHR 3680". AdisInsight.
  4. ^ Keam SJ (January 2023). "Rezvilutamide: First Approval". Drugs. 83 (2): 189–193. doi:10.1007/s40265-022-01831-y. PMID 36630077. S2CID 255593586.
  5. ^ a b Qin X, Han W, Luo H, Du C, Zou Q, Sun Z, et al. (2020). "SHR3680, a novel antiandrogen, for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A phase I/II study". Journal of Clinical Oncology. 38 (6_suppl): 90. doi:10.1200/JCO.2020.38.6_suppl.90. S2CID 214027454.


Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

Wikious
Boobota
Sagapedia